Abstract
Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Current Drug Therapy
Title: Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Volume: 1 Issue: 2
Author(s): Karim Bendjelid
Affiliation:
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Abstract: Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Export Options
About this article
Cite this article as:
Bendjelid Karim, Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930941
DOI https://dx.doi.org/10.2174/157488506776930941 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genomic Databases and the Search of Protein Targets for Protozoan Parasites
Current Drug Targets MicroRNAs in Atrial Fibrillation
Current Medicinal Chemistry Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Current Vascular Pharmacology Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Statins Therapy may Change a Course of Lung Fibrosis and Pulmonary Hypertension: A New Indication for Therapy or Just “Statinomania”?
Current Respiratory Medicine Reviews Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry The Impact of DIDS-Induced Inhibition of Voltage-Dependent Anion Channels (VDAC) on Cellular Response of Lymphoblastoid Cells to Ionizing Radiation
Medicinal Chemistry Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices
Current Topics in Medicinal Chemistry Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design Propofol Promotes Blood-Brain Barrier Breakdown and Heat Shock Protein (HSP 72 kd) Activation in the Developing Mouse Brain
CNS & Neurological Disorders - Drug Targets Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Luteolin Antagonizes Angiotensin II-Dependent Proliferation and Collagen Synthesis of Cultured rat Cardiac Fibroblasts
Current Pharmaceutical Biotechnology A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer s Disease, in Healthy Subjects and Patients
Current Clinical Pharmacology Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction
Current Pharmaceutical Design Advanced Glycation End Products and Cardiovascular Disease
Current Diabetes Reviews Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design